PolyPeptide Group (PPGN) H1 2025 earnings summary

Executive summary

• Revenue grew 24% year-over-year in H1 2025, reaching €167.1 million, mainly from commercial and metabolic therapeutics, with strong cash flow from disciplined working capital and customer prepayments.

• EBITDA increased to €4.4 million, supported by higher sales but offset by increased costs and investments.

• Expanded revolving credit facility to €151 million, enhancing financial flexibility for capacity expansion.

• Capacity expansion projects in Belgium, Sweden, and France are progressing on schedule, targeting full utilization by year-end.

• 2025 guidance revised upward and 2028 midterm outlook confirmed.

Financial highlights

• H1 2025 sales reached €167.1 million, up 23.7% year-over-year, driven by nearly €30 million growth in commercial business.

• EBITDA increased by €14.5 million, with margin at 2.7% (up 0.5 ppt year-over-year).

• Net result for the period: €-26.5 million, impacted by unfavorable FX revaluation.

• Operating cash flow reached €49.7 million, with period-end cash at €76.7 million.

• Net cash flow from investing activities was €-50.8 million, mainly due to capacity expansion.

Outlook and guidance

• 2025 revenue growth guidance revised to 13–20% at constant exchange rates, reflecting strong H1 momentum.

• EBITDA margin for 2025 expected in the high single-digit to low double-digit range.

• CapEx guidance increased to €100 million for 2025, reflecting accelerated customer demand.

• 2028 midterm guidance reconfirmed: double 2023 revenues, EBITDA margin approaching 25%, CapEx 15–20% of revenues.